Court Place Advisors LLC Has $2.47 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Court Place Advisors LLC reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,750 shares of the medical research company’s stock after selling 256 shares during the period. Thermo Fisher Scientific comprises about 0.8% of Court Place Advisors LLC’s investment portfolio, making the stock its 29th biggest position. Court Place Advisors LLC’s holdings in Thermo Fisher Scientific were worth $2,471,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Driehaus Capital Management LLC boosted its stake in Thermo Fisher Scientific by 75.0% in the second quarter. Driehaus Capital Management LLC now owns 1,524 shares of the medical research company’s stock worth $843,000 after purchasing an additional 653 shares in the last quarter. Creative Planning lifted its position in Thermo Fisher Scientific by 2.8% during the 2nd quarter. Creative Planning now owns 98,102 shares of the medical research company’s stock worth $54,250,000 after buying an additional 2,668 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its position in Thermo Fisher Scientific by 3.7% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 111,706 shares of the medical research company’s stock valued at $61,776,000 after acquiring an additional 4,030 shares in the last quarter. NewEdge Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 7.8% during the second quarter. NewEdge Advisors LLC now owns 24,696 shares of the medical research company’s stock worth $13,657,000 after purchasing an additional 1,784 shares in the last quarter. Finally, Wallace Advisory Group LLC grew its stake in shares of Thermo Fisher Scientific by 55.5% during the second quarter. Wallace Advisory Group LLC now owns 3,021 shares of the medical research company’s stock valued at $1,671,000 after purchasing an additional 1,078 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the sale, the chief executive officer now directly owns 111,192 shares of the company’s stock, valued at $58,960,669.92. The trade was a 8.25 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. In the last quarter, insiders have sold 34,850 shares of company stock worth $19,123,197. Corporate insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

TMO has been the topic of several research reports. Wells Fargo & Company reduced their price objective on Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. Redburn Atlantic started coverage on Thermo Fisher Scientific in a report on Monday, October 14th. They issued a “buy” rating and a $680.00 price target on the stock. TD Cowen upped their target price on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. Scotiabank assumed coverage on shares of Thermo Fisher Scientific in a research note on Monday, December 23rd. They set a “sector perform” rating and a $605.00 price target for the company. Finally, Bernstein Bank lifted their target price on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a report on Tuesday, October 22nd. Four research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average price target of $648.95.

Thermo Fisher Scientific Trading Up 1.5 %

TMO opened at $583.43 on Tuesday. The firm’s fifty day simple moving average is $533.60 and its 200 day simple moving average is $569.81. The stock has a market capitalization of $223.16 billion, a P/E ratio of 36.58, a P/E/G ratio of 3.82 and a beta of 0.76. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 12 month low of $493.30 and a 12 month high of $627.88.

Thermo Fisher Scientific announced that its Board of Directors has approved a share repurchase plan on Friday, November 15th that permits the company to repurchase $4.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 2% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date of this dividend was Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.78%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.